KG&L Capital Management LLC acquired a new stake in shares of Colgate-Palmolive (NYSE:CL – Free Report) during the third quarter, Holdings Channel reports. The fund acquired 2,744 shares of the company’s stock, valued at approximately $285,000.
A number of other institutional investors and hedge funds have also recently modified their holdings of CL. E Fund Management Hong Kong Co. Ltd. bought a new position in shares of Colgate-Palmolive during the second quarter valued at about $25,000. Continuum Advisory LLC grew its stake in shares of Colgate-Palmolive by 46.5% during the second quarter. Continuum Advisory LLC now owns 394 shares of the company’s stock valued at $38,000 after buying an additional 125 shares during the last quarter. Reston Wealth Management LLC bought a new position in shares of Colgate-Palmolive during the third quarter valued at about $42,000. Gradient Investments LLC grew its stake in shares of Colgate-Palmolive by 150.4% during the second quarter. Gradient Investments LLC now owns 666 shares of the company’s stock valued at $65,000 after buying an additional 400 shares during the last quarter. Finally, Financial Connections Group Inc. bought a new stake in shares of Colgate-Palmolive in the second quarter worth about $68,000. 80.41% of the stock is owned by institutional investors.
Colgate-Palmolive Price Performance
Shares of CL opened at $93.61 on Tuesday. The company has a market capitalization of $76.48 billion, a P/E ratio of 26.82, a price-to-earnings-growth ratio of 3.35 and a beta of 0.42. The company has a quick ratio of 0.28, a current ratio of 1.04 and a debt-to-equity ratio of 9.46. The firm has a 50 day moving average of $102.03 and a 200 day moving average of $98.40. Colgate-Palmolive has a twelve month low of $74.67 and a twelve month high of $109.30.
Colgate-Palmolive Dividend Announcement
Insider Activity at Colgate-Palmolive
In related news, Director Martina Hundmejean sold 2,313 shares of the firm’s stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $103.86, for a total transaction of $240,228.18. Following the completion of the sale, the director now owns 11,755 shares of the company’s stock, valued at $1,220,874.30. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Colgate-Palmolive news, Director Martina Hundmejean sold 2,313 shares of Colgate-Palmolive stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $103.86, for a total value of $240,228.18. Following the completion of the sale, the director now owns 11,755 shares of the company’s stock, valued at approximately $1,220,874.30. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Panagiotis Tsourapas sold 14,794 shares of Colgate-Palmolive stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $102.94, for a total transaction of $1,522,894.36. Following the completion of the sale, the insider now directly owns 5,146 shares of the company’s stock, valued at approximately $529,729.24. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 0.34% of the stock is owned by insiders.
Wall Street Analyst Weigh In
Several analysts recently issued reports on CL shares. Deutsche Bank Aktiengesellschaft cut Colgate-Palmolive from a “buy” rating to a “hold” rating and raised their target price for the stock from $107.00 to $109.00 in a research note on Monday, September 9th. TD Cowen cut their target price on Colgate-Palmolive from $115.00 to $110.00 and set a “buy” rating on the stock in a research note on Monday, October 28th. HSBC reissued a “hold” rating on shares of Colgate-Palmolive in a research note on Friday, July 26th. Barclays raised their target price on Colgate-Palmolive from $91.00 to $96.00 and gave the stock an “equal weight” rating in a research note on Monday, July 29th. Finally, StockNews.com cut Colgate-Palmolive from a “buy” rating to a “hold” rating in a research note on Tuesday, October 29th. One analyst has rated the stock with a sell rating, ten have given a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $105.11.
Colgate-Palmolive Profile
Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.
See Also
- Five stocks we like better than Colgate-Palmolive
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Intel: Is Now the Time to Be Brave?Â
- Why Are Stock Sectors Important to Successful Investing?
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- Insider Trading – What You Need to Know
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Want to see what other hedge funds are holding CL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Colgate-Palmolive (NYSE:CL – Free Report).
Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.